Mission Wealth Management LP Raises Stock Holdings in Johnson & Johnson $JNJ

Mission Wealth Management LP boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 66,671 shares of the company’s stock after purchasing an additional 7,340 shares during the quarter. Mission Wealth Management LP’s holdings in Johnson & Johnson were worth $12,362,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Commonwealth Retirement Investments LLC grew its position in shares of Johnson & Johnson by 1.2% during the third quarter. Commonwealth Retirement Investments LLC now owns 40,688 shares of the company’s stock worth $7,544,000 after buying an additional 470 shares in the last quarter. Money Concepts Capital Corp boosted its stake in Johnson & Johnson by 3.8% during the 3rd quarter. Money Concepts Capital Corp now owns 48,190 shares of the company’s stock valued at $8,935,000 after acquiring an additional 1,768 shares during the last quarter. Atlantic Union Bankshares Corp grew its holdings in Johnson & Johnson by 3.3% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 173,647 shares of the company’s stock worth $32,198,000 after acquiring an additional 5,497 shares in the last quarter. Guerra Advisors Inc bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $60,000. Finally, Nicholson Wealth Management Group LLC raised its stake in shares of Johnson & Johnson by 1.0% in the 3rd quarter. Nicholson Wealth Management Group LLC now owns 11,606 shares of the company’s stock valued at $2,152,000 after purchasing an additional 118 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $233.11 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The business’s 50 day moving average is $211.74 and its 200-day moving average is $192.73. The stock has a market cap of $561.62 billion, a PE ratio of 21.10, a price-to-earnings-growth ratio of 2.24 and a beta of 0.35. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $235.20.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. During the same period last year, the firm earned $2.04 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on JNJ shares. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. Finally, Barclays increased their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Multiple analyst upgrades and higher price targets — Morgan Stanley upgraded JNJ to Overweight and raised its PT to $262, RBC lifted its PT to $255 with an Outperform rating, BofA nudged its PT to $227, and other outlets report a PT raised to $265; these moves signal stronger analyst conviction on JNJ’s earnings and margin outlook. Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262 RBC Raises Price Target on Johnson & Johnson to $255 BofA lifts PT on Johnson & Johnson (JNJ) to $227 from $221 – here’s why Johnson & Johnson (NYSE:JNJ) Price Target Raised to $265.00
• Positive Sentiment: MedTech/product progress: J&J MedTech announced updates to its Varipulse product and a new ultrasound catheter, which can expand procedure use and revenue potential in vascular/interventional markets. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter
• Positive Sentiment: Commercial rollout: J&J launched the first daily-disposable multifocal toric contact lens for astigmatic presbyopic patients in the U.K. and Ireland (ACUVUE®), supporting the consumer/vision revenue stream. Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia
• Positive Sentiment: Investor access: Management will present at the TD Cowen Health Care Conference on March 3 — a chance to hear updated guidance, pipeline milestones and margin drivers directly from management. Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Context piece: A Forbes analysis reviews JNJ’s ~52% run over the past nine months, attributing gains to improved earnings, product wins and legal progress — useful background but not an immediate catalyst. What’s Behind The 50% Surge In JNJ Stock?

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.